Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PLSE |
---|---|---|
09:32 ET | 1034 | 18.5 |
09:33 ET | 100 | 18.4 |
09:42 ET | 200 | 18.78 |
09:44 ET | 1639 | 18.7 |
09:48 ET | 870 | 18.9 |
10:00 ET | 100 | 18.77 |
10:08 ET | 1100 | 18.6 |
10:09 ET | 200 | 18.5 |
10:11 ET | 100 | 18.52 |
10:13 ET | 150 | 18.65 |
10:18 ET | 100 | 18.53 |
10:24 ET | 2429 | 18.5 |
10:27 ET | 405 | 18.5 |
10:29 ET | 100 | 18.575 |
10:31 ET | 175 | 18.28 |
10:38 ET | 1100 | 18.53 |
10:44 ET | 1150 | 18.27 |
11:02 ET | 6872 | 17.96 |
11:03 ET | 1153 | 17.99 |
11:05 ET | 2759 | 17.79 |
11:12 ET | 3935 | 17.66 |
11:14 ET | 1032 | 17.765 |
11:16 ET | 300 | 17.87 |
11:21 ET | 100 | 17.99 |
11:23 ET | 200 | 17.95 |
11:25 ET | 200 | 17.95 |
11:30 ET | 369 | 17.965 |
11:36 ET | 110 | 17.99 |
11:38 ET | 273 | 17.84 |
11:43 ET | 1611 | 17.795 |
11:48 ET | 200 | 17.77 |
11:50 ET | 100 | 17.67 |
11:54 ET | 700 | 17.82 |
11:57 ET | 200 | 17.68 |
11:59 ET | 5617 | 17.58 |
12:03 ET | 200 | 17.58 |
12:06 ET | 250 | 17.5 |
12:10 ET | 100 | 17.46 |
12:24 ET | 200 | 17.4529 |
12:30 ET | 1065 | 17.61 |
12:33 ET | 524 | 17.6 |
12:42 ET | 2535 | 17.54 |
12:48 ET | 457 | 17.57 |
12:50 ET | 200 | 17.42 |
12:51 ET | 1100 | 17.5 |
12:53 ET | 100 | 17.54 |
12:57 ET | 1300 | 17.43 |
01:00 ET | 2025 | 17.55 |
01:04 ET | 1641 | 17.5 |
01:06 ET | 3223 | 17.61 |
01:09 ET | 585 | 17.65 |
01:11 ET | 425 | 17.65 |
01:13 ET | 100 | 17.62 |
01:15 ET | 610 | 17.62 |
01:18 ET | 200 | 17.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Pulse Biosciences Inc | 1.2B | -21.9x | --- |
CeriBell Inc | 1.0B | 0.0x | --- |
Nano-X Imaging Ltd | 428.8M | -6.5x | --- |
IRadimed Corp | 726.8M | 38.7x | +21.02% |
Atlantic International Corp | 249.7M | -0.6x | --- |
Orchestra Biomed Holdings Inc | 231.9M | -3.8x | --- |
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.75 |
EPS | $-0.81 |
Book Value | $0.80 |
P/E Ratio | -21.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.